Contraline has appointed Dr. Yelena Tropsha to the role of chief technology officer. Dr. Tropsha brings to Contraline over 25 years of medical device experience, from front-end innovation to commercialization.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
848.9 DKK | -1.50% | -7.44% | +9.90% |
02-27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
02-14 | COLOPLAST : Q1 24: Many more positives beyond the margin beat |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.90% | 27.84B | |
-29.83% | 3.04B | |
-14.68% | 2.56B | |
+11.64% | 2.33B | |
+2.96% | 1.99B | |
-11.65% | 1.87B | |
-1.67% | 1.49B | |
+2.19% | 1.27B | |
+3.72% | 1.12B | |
+16.22% | 1.15B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Contraline Names Yelena Tropsha as CTO